Brief: Biostage says cellspan implants being advanced, tested in preclinical studies
21/07/2016 13:56
July 21 (Reuters) - Biostage BSTG.O :
* Biostage appoints Harout Dersimonian, PH.D. as chief
scientific officer to oversee cell biology, materials science
and other research underlying its organ implant development
* Cellspan implants being advanced and tested in preclinical
studies; expects filing IND with U.S. FDA in late 2016
Source text for Eikon: ID:nPn5F1Y6xa
Further company coverage: BSTG.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer